Gene: AR ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs864622007
rs864622007
AR
A 0.830 GeneticVariation CLINVAR

dbSNP: rs864622007
rs864622007
AR
0.830 GeneticVariation UNIPROT

dbSNP: rs864622007
rs864622007
AR
0.830 GeneticVariation BEFREE This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6). 11906285

2002
dbSNP: rs864622007
rs864622007
AR
0.830 GeneticVariation BEFREE Our results indicate that the specific amino acid residue at position 701, its interaction with the backbone of Ser(778), and the steroidal 17alpha-hydroxyl group of the ligand are all important for the distinct transcriptional responses to progesterone and cortisol of AR mutants, including the prostate cancer mutant L701H. 20007693

2010
dbSNP: rs864622007
rs864622007
AR
0.830 GeneticVariation BEFREE The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth. 11956172

2002
dbSNP: rs137852564
rs137852564
AR
A 0.800 CausalMutation CLINVAR

dbSNP: rs137852564
rs137852564
AR
0.800 GeneticVariation UNIPROT

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen. 17312014

2007
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation UNIPROT

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer. 19856921

2009
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. 25409505

2014
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6. 15790678

2005
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A. 18007998

2007
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression. 16636679

2006
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis. 21383160

2011
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6). 11906285

2002
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms. 24874833

2014
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth. 11956172

2002
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc. 25358634

2015
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer. 17991730

2008
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR. 24167630

2013
dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR). 23813737

2013
dbSNP: rs137852593
rs137852593
AR
0.740 GeneticVariation UNIPROT

dbSNP: rs137852593
rs137852593
AR
0.740 GeneticVariation BEFREE R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected. 14665948

2004
dbSNP: rs137852593
rs137852593
AR
0.740 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000